DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that the company will [...]
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of [...]
SAN DIEGO, May 20, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide- SAN DIEGO, May 13, 2020 /PRNewswire/ -- DTx [...]
DTx Pharma announced today the final closing of a Series A financing totaling $10.6 million dollars. The round was led by San Diego-based FBV [...]
The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company [...]
DTx received a notice of award in September for our first CNS focused grant, targeting the Tau gene/protein implicated in FTLD’s such as PSP as [...]
San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2019 [...]
Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, was named by the San Diego Venture Group (SDVG) [...]
San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2018 [...]